Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

The SETD6 Methyltransferase Plays an Essential Role in Hippocampus-Dependent Memory Formation.

Webb WM, Irwin AB, Pepin ME, Henderson BW, Huang V, Butler AA, Herskowitz JH, Wende AR, Cash AE, Lubin FD.

Biol Psychiatry. 2019 Jun 12. pii: S0006-3223(19)31415-5. doi: 10.1016/j.biopsych.2019.05.022. [Epub ahead of print]

PMID:
31378303
2.

Fasudil or genetic depletion of ROCK1 or ROCK2 induces anxiety-like behaviors.

Greathouse KM, Henderson BW, Gentry EG, Herskowitz JH.

Behav Brain Res. 2019 Nov 5;373:112083. doi: 10.1016/j.bbr.2019.112083. Epub 2019 Jul 11.

PMID:
31302146
3.

Pharmacologic inhibition of LIMK1 provides dendritic spine resilience against β-amyloid.

Henderson BW, Greathouse KM, Ramdas R, Walker CK, Rao TC, Bach SV, Curtis KA, Day JJ, Mattheyses AL, Herskowitz JH.

Sci Signal. 2019 Jun 25;12(587). pii: eaaw9318. doi: 10.1126/scisignal.aaw9318.

PMID:
31239325
4.

Distinct and complementary functions of rho kinase isoforms ROCK1 and ROCK2 in prefrontal cortex structural plasticity.

Greathouse KM, Boros BD, Deslauriers JF, Henderson BW, Curtis KA, Gentry EG, Herskowitz JH.

Brain Struct Funct. 2018 Dec;223(9):4227-4241. doi: 10.1007/s00429-018-1748-4. Epub 2018 Sep 8.

PMID:
30196430
5.

α-Synuclein fibril-induced paradoxical structural and functional defects in hippocampal neurons.

Froula JM, Henderson BW, Gonzalez JC, Vaden JH, Mclean JW, Wu Y, Banumurthy G, Overstreet-Wadiche L, Herskowitz JH, Volpicelli-Daley LA.

Acta Neuropathol Commun. 2018 May 1;6(1):35. doi: 10.1186/s40478-018-0537-x.

6.

Rho-associated protein kinase 1 (ROCK1) is increased in Alzheimer's disease and ROCK1 depletion reduces amyloid-β levels in brain.

Henderson BW, Gentry EG, Rush T, Troncoso JC, Thambisetty M, Montine TJ, Herskowitz JH.

J Neurochem. 2016 Aug;138(4):525-31. doi: 10.1111/jnc.13688. Epub 2016 Jul 1.

7.

Rho Kinase Inhibition as a Therapeutic for Progressive Supranuclear Palsy and Corticobasal Degeneration.

Gentry EG, Henderson BW, Arrant AE, Gearing M, Feng Y, Riddle NC, Herskowitz JH.

J Neurosci. 2016 Jan 27;36(4):1316-23. doi: 10.1523/JNEUROSCI.2336-15.2016.

8.

Intraoperative optical assessment of photodynamic therapy response of superficial oral squamous cell carcinoma.

Rohrbach DJ, Rigual N, Arshad H, Tracy EC, Cooper MT, Shafirstein G, Wilding G, Merzianu M, Baumann H, Henderson BW, Sunar U.

J Biomed Opt. 2016 Jan;21(1):18002. doi: 10.1117/1.JBO.21.1.018002. No abstract available.

9.

A Phase I Study of Light Dose for Photodynamic Therapy Using 2-[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a for the Treatment of Non-Small Cell Carcinoma In Situ or Non-Small Cell Microinvasive Bronchogenic Carcinoma: A Dose Ranging Study.

Dhillon SS, Demmy TL, Yendamuri S, Loewen G, Nwogu C, Cooper M, Henderson BW.

J Thorac Oncol. 2016 Feb;11(2):234-41. doi: 10.1016/j.jtho.2015.10.020. Epub 2015 Dec 22.

10.

Mutant human torsinA, responsible for early-onset dystonia, dominantly suppresses GTPCH expression, dopamine levels and locomotion in Drosophila melanogaster.

Wakabayashi-Ito N, Ajjuri RR, Henderson BW, Doherty OM, Breakefield XO, O'Donnell JM, Ito N.

Biol Open. 2015 Apr 17;4(5):585-95. doi: 10.1242/bio.201411080.

11.

Photodynamic therapy with 3-(1'-hexyloxyethyl) pyropheophorbide-a for early-stage cancer of the larynx: Phase Ib study.

Shafirstein G, Rigual NR, Arshad H, Cooper MT, Bellnier DA, Wilding G, Tan W, Merzianu M, Henderson BW.

Head Neck. 2016 Apr;38 Suppl 1:E377-83. doi: 10.1002/hed.24003. Epub 2015 Jun 29.

12.

A prospective study of pain control by a 2-step irradiance schedule during topical photodynamic therapy of nonmelanoma skin cancer.

Zeitouni NC, Sunar U, Rohrbach DJ, Paquette AD, Bellnier DA, Shi Y, Wilding G, Foster TH, Henderson BW.

Dermatol Surg. 2014 Dec;40(12):1390-4. doi: 10.1097/DSS.0000000000000183.

13.

Photodynamic therapy with 3-(1'-hexyloxyethyl) pyropheophorbide a for cancer of the oral cavity.

Rigual N, Shafirstein G, Cooper MT, Baumann H, Bellnier DA, Sunar U, Tracy EC, Rohrbach DJ, Wilding G, Tan W, Sullivan M, Merzianu M, Henderson BW.

Clin Cancer Res. 2013 Dec 1;19(23):6605-13. doi: 10.1158/1078-0432.CCR-13-1735. Epub 2013 Oct 2.

14.

Quantification of PpIX concentration in basal cell carcinoma and squamous cell carcinoma models using spatial frequency domain imaging.

Sunar U, Rohrbach DJ, Morgan J, Zeitouni N, Henderson BW.

Biomed Opt Express. 2013 Apr 1;4(4):531-7. doi: 10.1364/BOE.4.000531. Epub 2013 Mar 6.

15.

A retrospective review of pain control by a two-step irradiance schedule during topical ALA-photodynamic therapy of non-melanoma skin cancer.

Zeitouni NC, Paquette AD, Housel JP, Shi Y, Wilding GE, Foster TH, Henderson BW.

Lasers Surg Med. 2013 Feb;45(2):89-94. doi: 10.1002/lsm.22118. Epub 2013 Feb 6.

16.

Interlesion differences in the local photodynamic therapy response of oral cavity lesions assessed by diffuse optical spectroscopies.

Rohrbach DJ, Rigual N, Tracy E, Kowalczewski A, Keymel KL, Cooper MT, Mo W, Baumann H, Henderson BW, Sunar U.

Biomed Opt Express. 2012 Sep 1;3(9):2142-53. Epub 2012 Aug 16.

17.

Interleukin-1α is the major alarmin of lung epithelial cells released during photodynamic therapy to induce inflammatory mediators in fibroblasts.

Tracy EC, Bowman MJ, Henderson BW, Baumann H.

Br J Cancer. 2012 Oct 23;107(9):1534-46. doi: 10.1038/bjc.2012.429. Epub 2012 Sep 20.

18.

Photodynamic therapy (PDT) using HPPH for the treatment of precancerous lesions associated with Barrett's esophagus.

Nava HR, Allamaneni SS, Dougherty TJ, Cooper MT, Tan W, Wilding G, Henderson BW.

Lasers Surg Med. 2011 Sep;43(7):705-12. doi: 10.1002/lsm.21112.

19.

Cell-type selective phototoxicity achieved with chlorophyll-a derived photosensitizers in a co-culture system of primary human tumor and normal lung cells.

Tracy EC, Bowman MJ, Pandey RK, Henderson BW, Baumann H.

Photochem Photobiol. 2011 Nov-Dec;87(6):1405-18. doi: 10.1111/j.1751-1097.2011.00992.x. Epub 2011 Oct 3.

20.

Monitoring blood flow responses during topical ALA-PDT.

Becker TL, Paquette AD, Keymel KR, Henderson BW, Sunar U.

Biomed Opt Express. 2010 Dec 15;2(1):123-30. doi: 10.1364/BOE.2.000123.

21.

Conjugation of 2-(1'-hexyloxyethyl)-2-devinylpyropheophorbide-a (HPPH) to carbohydrates changes its subcellular distribution and enhances photodynamic activity in vivo.

Zheng X, Morgan J, Pandey SK, Chen Y, Tracy E, Baumann H, Missert JR, Batt C, Jackson J, Bellnier DA, Henderson BW, Pandey RK.

J Med Chem. 2009 Jul 23;52(14):4306-18. doi: 10.1021/jm9001617.

22.

Light delivery over extended time periods enhances the effectiveness of photodynamic therapy.

Seshadri M, Bellnier DA, Vaughan LA, Spernyak JA, Mazurchuk R, Foster TH, Henderson BW.

Clin Cancer Res. 2008 May 1;14(9):2796-805. doi: 10.1158/1078-0432.CCR-07-4705.

23.

Interleukin-6 trans signalling enhances photodynamic therapy by modulating cell cycling.

Wei LH, Baumann H, Tracy E, Wang Y, Hutson A, Rose-John S, Henderson BW.

Br J Cancer. 2007 Dec 3;97(11):1513-22. Epub 2007 Nov 6.

24.

Photodynamic therapy enhancement of antitumor immunity is regulated by neutrophils.

Kousis PC, Henderson BW, Maier PG, Gollnick SO.

Cancer Res. 2007 Nov 1;67(21):10501-10.

25.

Cross-linking of signal transducer and activator of transcription 3--a molecular marker for the photodynamic reaction in cells and tumors.

Henderson BW, Daroqui C, Tracy E, Vaughan LA, Loewen GM, Cooper MT, Baumann H.

Clin Cancer Res. 2007 Jun 1;13(11):3156-63.

26.

Purpurinimide carbohydrate conjugates: effect of the position of the carbohydrate moiety in photosensitizing efficacy.

Pandey SK, Zheng X, Morgan J, Missert JR, Liu TH, Shibata M, Bellnier DA, Oseroff AR, Henderson BW, Dougherty TJ, Pandey RK.

Mol Pharm. 2007 May-Jun;4(3):448-64. Epub 2007 Mar 21.

PMID:
17373821
27.

Fluence rate as a modulator of PDT mechanisms.

Henderson BW, Busch TM, Snyder JW.

Lasers Surg Med. 2006 Jun;38(5):489-93. Review.

PMID:
16615136
28.

A novel approach to a bifunctional photosensitizer for tumor imaging and phototherapy.

Chen Y, Gryshuk A, Achilefu S, Ohulchansky T, Potter W, Zhong T, Morgan J, Chance B, Prasad PN, Henderson BW, Oseroff A, Pandey RK.

Bioconjug Chem. 2005 Sep-Oct;16(5):1264-74.

PMID:
16173807
29.

Synthesis and photosensitizing efficacy of isomerically pure bacteriopurpurinimides.

Chen Y, Sumlin A, Morgan J, Gryshuk A, Oseroff A, Henderson BW, Dougherty TJ, Pandey RK.

J Med Chem. 2004 Sep 23;47(20):4814-7.

PMID:
15369384
30.

Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors.

Henderson BW, Gollnick SO, Snyder JW, Busch TM, Kousis PC, Cheney RT, Morgan J.

Cancer Res. 2004 Mar 15;64(6):2120-6.

31.

Photodynamic therapy: a means to enhanced drug delivery to tumors.

Snyder JW, Greco WR, Bellnier DA, Vaughan L, Henderson BW.

Cancer Res. 2003 Dec 1;63(23):8126-31.

32.

Role of cytokines in photodynamic therapy-induced local and systemic inflammation.

Gollnick SO, Evans SS, Baumann H, Owczarczak B, Maier P, Vaughan L, Wang WC, Unger E, Henderson BW.

Br J Cancer. 2003 Jun 2;88(11):1772-9.

33.

Generation of effective antitumor vaccines using photodynamic therapy.

Gollnick SO, Vaughan L, Henderson BW.

Cancer Res. 2002 Mar 15;62(6):1604-8.

34.

Bacteriopurpurinimides: highly stable and potent photosensitizers for photodynamic therapy.

Chen Y, Graham A, Potter W, Morgan J, Vaughan L, Bellnier DA, Henderson BW, Oseroff A, Dougherty TJ, Pandey RK.

J Med Chem. 2002 Jan 17;45(2):255-8.

PMID:
11784129
35.

IL-10 does not play a role in cutaneous Photofrin photodynamic therapy-induced suppression of the contact hypersensitivity response.

Gollnick SO, Musser DA, Oseroff AR, Vaughan L, Owczarczak B, Henderson BW.

Photochem Photobiol. 2001 Dec;74(6):811-6.

PMID:
11783937
36.

Synthesis, photophysical properties, tumor uptake, and preliminary in vivo photosensitizing efficacy of a homologous series of 3-(1'-alkyloxy)ethyl-3-devinylpurpurin-18-N-alkylimides with variable lipophilicity.

Zheng G, Potter WR, Camacho SH, Missert JR, Wang G, Bellnier DA, Henderson BW, Rodgers MA, Dougherty TJ, Pandey RK.

J Med Chem. 2001 May 10;44(10):1540-59.

PMID:
11334564
37.

Activation of the IL-10 gene promoter following photodynamic therapy of murine keratinocytes.

Gollnick SO, Lee BY, Vaughan L, Owczarczak B, Henderson BW.

Photochem Photobiol. 2001 Feb;73(2):170-7.

38.

Photofrin photodynamic therapy can significantly deplete or preserve oxygenation in human basal cell carcinomas during treatment, depending on fluence rate.

Henderson BW, Busch TM, Vaughan LA, Frawley NP, Babich D, Sosa TA, Zollo JD, Dee AS, Cooper MT, Bellnier DA, Greco WR, Oseroff AR.

Cancer Res. 2000 Feb 1;60(3):525-9.

40.

Potentiation of photodynamic therapy antitumor activity in mice by nitric oxide synthase inhibition is fluence rate dependent.

Henderson BW, Sitnik-Busch TM, Vaughan LA.

Photochem Photobiol. 1999 Jul;70(1):64-71.

PMID:
10420844
41.
42.

Photodynamic therapy.

Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q.

J Natl Cancer Inst. 1998 Jun 17;90(12):889-905. Review.

43.

The effect of fluence rate on tumor and normal tissue responses to photodynamic therapy.

Sitnik TM, Henderson BW.

Photochem Photobiol. 1998 Apr;67(4):462-6.

PMID:
9559590
44.

An in vivo quantitative structure-activity relationship for a congeneric series of pyropheophorbide derivatives as photosensitizers for photodynamic therapy.

Henderson BW, Bellnier DA, Greco WR, Sharma A, Pandey RK, Vaughan LA, Weishaupt KR, Dougherty TJ.

Cancer Res. 1997 Sep 15;57(18):4000-7.

45.

Altered expression of interleukin 6 and interleukin 10 as a result of photodynamic therapy in vivo.

Gollnick SO, Liu X, Owczarczak B, Musser DA, Henderson BW.

Cancer Res. 1997 Sep 15;57(18):3904-9.

46.

Correlation between site II-specific human serum albumin (HSA) binding affinity and murine in vivo photosensitizing efficacy of some Photofrin components.

Tsuchida T, Zheng G, Pandey RK, Potter WR, Bellnier DA, Henderson BW, Kato H, Dougherty TJ.

Photochem Photobiol. 1997 Aug;66(2):224-8.

PMID:
9277141
47.

Alkyl ether analogs of chlorophyll-a derivatives: Part 1. Synthesis, photophysical properties and photodynamic efficacy.

Pandey RK, Sumlin AB, Constantine S, Aoudla M, Potter WR, Bellnier DA, Henderson BW, Rodgers MA, Smith KM, Dougherty TJ.

Photochem Photobiol. 1996 Jul;64(1):194-204.

PMID:
8787014
48.

The validation of a new vascular damage assay for photodynamic therapy agents.

Bellnier DA, Potter WR, Vaughan LA, Sitnik TM, Parsons JC, Greco WR, Whitaker J, Johnson P, Henderson BW.

Photochem Photobiol. 1995 Nov;62(5):896-905.

PMID:
8570729
49.

Sites of photodamage in vivo and in vitro by a cationic porphyrin.

Kessel D, Woodburn K, Henderson BW, Chang CK.

Photochem Photobiol. 1995 Nov;62(5):875-81.

PMID:
8570726
50.

Photosensitization of murine tumor, vasculature and skin by 5-aminolevulinic acid-induced porphyrin.

Henderson BW, Vaughan L, Bellnier DA, van Leengoed H, Johnson PG, Oseroff AR.

Photochem Photobiol. 1995 Oct;62(4):780-9.

PMID:
7480155

Supplemental Content

Loading ...
Support Center